| __timestamp | Amphastar Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 241751000 |
| Thursday, January 1, 2015 | 174172000 | 322292000 |
| Friday, January 1, 2016 | 150976000 | 344320000 |
| Sunday, January 1, 2017 | 149380000 | 374644000 |
| Monday, January 1, 2018 | 187681000 | 1820000 |
| Tuesday, January 1, 2019 | 190434000 | 4000000 |
| Wednesday, January 1, 2020 | 206506000 | 12000000 |
| Friday, January 1, 2021 | 238029000 | 11000000 |
| Saturday, January 1, 2022 | 250127000 | 14000000 |
| Sunday, January 1, 2023 | 293274000 | 9133000 |
| Monday, January 1, 2024 | 11215000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. This analysis delves into the cost of revenue trends for Ionis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Amphastar consistently demonstrated a more stable cost structure, with an average cost of revenue around 200 million USD, peaking at approximately 293 million USD in 2023. In contrast, Ionis exhibited significant volatility, with costs ranging from a mere 1.8 million USD in 2018 to a high of 375 million USD in 2017. This fluctuation suggests a strategic pivot or operational challenges. Notably, Amphastar's cost efficiency improved by nearly 84% from 2014 to 2023, while Ionis faced a 96% reduction in 2018, indicating potential restructuring. Understanding these dynamics offers valuable insights into each company's operational strategies and market positioning.
Cost Insights: Breaking Down Sanofi and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Pharming Group N.V. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored